Before visiting, please review our current visitor policies and COVID-19 information.
Testing the effects of mk-3475 (pembrolizumab) with or without the usual chemotherapy treatment for patients 70 years of age and older with advanced non-small cell lung cancer.
To find out if patients aged 70 years or older have different side effects than younger patients from treatment with the usual approach for non-small cell lung cancer.
DiagnosisPatients who have non-small cell lung cancer that has spread to other parts of your body and will be treated with the drug called MK-3475 (pembrolizumab) with or without chemotherapy.
Stage IV or recurrent metastatic non-small cell lung cancer.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
This study has 2 study groups. Each cycle lasts 21 days (you may receive the pembrolizumab once every 42 days instead).
- Group A: Patients in this group will get MK-3475 (pembrolizumab) alone.
- Group B: Patients in this group will get MK-3475 (pembrolizumab) along with two chemotherapy drugs called pemetrexed and carboplatin on the first day of each cycle.
For more information, visit ClinicalTrials.gov
Key Participation Requirements
Male or Female
70 years or older
Methodist Health System Trial Code